Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled double blind clinical trial
et al., Endocrine Practice, doi:10.1016/j.eprac.2021.09.016
, Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood.., Endocrine Practice, doi:10.1016/j.eprac.2021.09.016
RCT 106 hospitalized patients with vitamin D levels <30ng/ml in Iran, 53 treated with calcifediol, showing that treatment was able to correct vitamin D deficiency/insufficiency, resulting in improved immune system function. Hospitalization, ICU duration, ventilation, and mortality was lower with treatment, without reaching statistical significance with the small sample size. The dosage used in this trial was much lower than other trials.Although the 40% lower mortality is not statistically significant, it is consistent with the significant 36% lower mortality [28‑44%] from meta analysis of the 60 mortality results to date.
|
risk of death, 40.0% lower, RR 0.60, p = 0.72, treatment 3 of 53 (5.7%), control 5 of 53 (9.4%), NNT 26.
|
|
risk of mechanical ventilation, 60.0% lower, RR 0.40, p = 0.44, treatment 2 of 53 (3.8%), control 5 of 53 (9.4%), NNT 18.
|
|
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.42, treatment 6 of 53 (11.3%), control 10 of 53 (18.9%), NNT 13.
|
|
ICU time, 36.4% lower, relative time 0.64, p = 0.20, treatment 53, control 53.
|
|
hospitalization time, 16.7% lower, relative time 0.83, p = 0.10, treatment 53, control 53.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Maghbooli et al., 13 Oct 2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors, dosage calcifediol 25μg daily, mean daily dose.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.
Journal Pre-proof
Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction
in the blood neutrophil-to-lymphocyte ratio marker of disease severity in patients
hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled
double blind clinical trial
Zhila Maghbooli, Ph.D, Mohammad Ali Sahraian, M.D, Saeid Reza JamaliMoghadam, M.D, Asma Asadi, M.D. Azadeh zarei, Abolfazl Zendehdel, M.D, Tarlan
Varzandi, M.S.c, Sara Mohammadnabi, B.D, Neda Alijani, M.D, Mehrdad Karimi,
Arash Shirvani, M.D., Ph.D, Michael F. Holick, Ph.D., M.D
PII:
S1530-891X(21)01259-3
DOI:
https://doi.org/10.1016/j.eprac.2021.09.016
Reference:
EPRAC 274
To appear in:
Endocrine Practice
Received Date: 3 June 2021
Revised Date:
15 September 2021
Accepted Date: 15 September 2021
Please cite this article as: Maghbooli Z, Sahraian MA, Jamali-Moghadam SR, Asadi A, Azadeh zarei
MD, Zendehdel A, Varzandi T, Mohammadnabi S, Alijani N, Karimi M, Shirvani A, Holick MF, Treatment
with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-tolymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter,
randomized, placebo-controlled double blind clinical trial, Endocrine Practice (2021), doi: https://
doi.org/10.1016/j.eprac.2021.09.016.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier Inc. on behalf of the AACE.
1
2
Title:
3
Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood
4
neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19:
5
a pilot, multicenter, randomized, placebo-controlled double blind clinical trial
6
Abbreviated title:
8
Therapeutic effects of oral 25-hydroxyvitamin D3 on COVID-19
of
7
ro
9
Authors:, Zhila Maghbooli1, Ph.D., Mohammad Ali Sahraian1,M.D., Saeid Reza Jamali-Moghadam2,M.D., Asma
11
Asadi3, Azadeh zarei4 ,M.D.,Abolfazl Zendehdel5,M.D., Tarlan Varzandi1, M.S.c, Sara Mohammadnabi1, B.D., Neda
12
Alijani6,M.D., Mehrdad Karimi4, Arash Shirvani7, M.D., Ph.D., Michael F. Holick*7, Ph.D.,M.D.
re
-p
10
lP
13
1. Multiple..
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.